» Pharmasset Reports Preliminary Results Of A 4-week Combination Study Of R7128 For The Treatment Of Chronic Hepatitis C
Pharmasset, Inc. (Nasdaq: VRUS) announces the preliminary results of the third cohort of a 4-week Phase 1 clinical trial evaluating R7128 1000mg twice daily (BID) in combination with the standard of…